Molecular Partners Presents Data of MP0250 in an All-Comer Phase 1-Study in Solid Tumor Patients and Updates on Phase 2 Studies
Zurich‐Schlieren, October 9, 2016. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a powerful new class of therapies known as DARPin® therapies, announces additional details about its ongoing clinical oncology program MP0250.
M.R. Middleton, Professor of Experimental Cancer Medicine, Department of Oncology at the University of Oxford, UK presents today the completed phase 1 dose escalation interim results of MP0250 at the poster session ‘Developmental Therapeutics’ at the Conference of the European Society of Medical Oncology (ESMO). The poster is available under this link.
MP0250 is a multi-DARPin® product consisting of four domains targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and also binds to human serum albumin (HSA) to increase the plasma half-life and potentially tissue penetration.
Prof. M.R. Middleton commented: “MP0250 used as single agent is the first DARPin® drug candidate to be studied in humans as systemic treatment. The drug is generally well tolerated and the side effect profile is consistent with profound inhibition of the VEGF pathway. We have seen encouraging signs of clinical activity in these heavily pretreated patients, with two patients showing significant reduction of tumor burden and 6 patients having prolonged stable disease. MP0250 has the potential to become a new therapeutic in treating various tumor types.”
These data, now based on the total enrollment of 24 patients, are an important milestone in the development of DARPin® proteins as anticancer agents and expand the results that were published at the AACR-NCI-EORTC conference in November 2015:
- MP0250 was well tolerated at the higher dose levels (up to 8 mg/kg administered every 2 weeks). This was assigned as the maximally tolerated dose (MTD). Toxicities came primarily from the inhibition of VEGF, including dose-limiting toxicities of acute left ventricular failure, nephrotic syndrome and hypertension, gastrointestinal hemorrhage and thrombotic microangiopathy.
- MP0250 had a half-life of about 12 days and shows full exposure in all patients over the whole treatment period at all doses.
Update on phase 2 strategy for MP0250
The first phase 2 study will examine MP0250 in combination with bortezomib and dexamethasone in patients with multiple myeloma who have failed proteasome and IMiD based standard therapies. The first regulatory submission for such study is planned in Q4 2016.
Based on the encouraging data from phase 1 in solid tumors, Molecular Partners decided to initiate an additional phase 2 study for a solid tumor indication. Study details will be disclosed in H1 2017.
About the DARPin® technology
Molecular Partners is progressing programs in ophthalmology in partnership with Allergan and in oncology with a proprietary pipeline of DARPin® drug candidates. The most advanced assets globally is abicipar, a molecule currently in phase 3 which is being advanced by Allergan. Abicipar is being followed by several DARPins® for various ophthalmic indications. The most advanced systemic DARPin® molecule, MP0250, is in clinical development for solid tumors and is moving to phase 2 for hematological and solid tumors. The second most advanced oncology DARPin® drug candidate is MP0274, which has broad anti-HER activity, inhibiting HER1, HER2, and HER3-mediated downstream signaling via Her2 and leading to induction of apoptosis. MP0274 is currently in preclinical development. There is a growing pipeline of immune-oncological treatments following the two proprietary lead assets.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPin® therapies. DARPin® therapies are potent, specific, and versatile small proteins, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology has the potential to offer a multi-specific approach to treatment, which enables the DARPin® therapies to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPin® therapies have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. DARPin® is a registered trademark owned by Molecular Partners AG.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details please contact:
Dr. Christian Zahnd, CEO
Tel: +41 (0) 44 755 77 00
PD Dr. Andreas Harstrick, CMO
Tel: +41 (0) 44 755 77 00
Tel: +41 (0) 43 344 42 42
Susan A. Noonan Communications, LLC
Tel: +1 212 966 3650
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements, assessments or intentions.